PMID- 37337740
OWN - NLM
STAT- MEDLINE
DCOM- 20251006
LR  - 20251006
IS  - 2724-6116 (Electronic)
IS  - 2724-6116 (Linking)
VI  - 50
IP  - 3
DP  - 2025 Sep
TI  - Results of semaglutide in patients older than 70 years, a real-world study of 
      efficacy and safety.
PG  - 296-301
LID - 10.23736/S2724-6507.23.03985-4 [doi]
AB  - BACKGROUND: The aim of this study is to investigate the use of once-weekly 
      semaglutide in a real population of patients with type 2 diabetes mellitus (T2DM) 
      over 70 years in two Spanish hospitals. METHODS: An observational, retrospective, 
      and multicenter clinical study was designed. It included 60 patients with T2DM, 
      with a mean age of 76.5 years, 63.3% women, and a mean of 15.5 years of evolution 
      of T2DM, all managed in the outpatient clinical setting. The primary endpoint was 
      the change in HbA<inf>1c</inf> from baseline to the end of the study. The 
      secondary endpoints included changes in body weight and the proportion of 
      patients achieving HbA<inf>1c</inf> <7.0% and body weight loss >5%. RESULTS: 
      After 12 months of follow-up, the reductions in HbA<inf>1c</inf> were -0.61+/-0.9% 
      (P<0.0001) in the total cohort. Body weight reductions were -8.2+/-5.3 kg 
      (P<0.0001). Overall, 67% reached the objective of an HbA<inf>1c</inf> level of 
      <7%, and 73% achieved a weight loss of >/=5%. CONCLUSIONS: In routine clinical 
      practice in Spain, the use of semaglutide once a week was associated with 
      statistically significant and clinically relevant improvements in 
      HbA<inf>1c</inf> and body weight in adults aged over 70 years with T2DM, without 
      notable adverse effects, which supports real-world use.
FAU - Garcia DE Lucas, Maria D
AU  - Garcia DE Lucas MD
AD  - Department of Internal Medicine, Costa del Sol Hospital, Marbella, Spain.
FAU - Perez-Belmonte, Luis
AU  - Perez-Belmonte L
AD  - Department of Internal Medicine, Regional University Hospital and Biomedical 
      Research Institute, Malaga, Spain.
FAU - Aviles-Bueno, Beatriz
AU  - Aviles-Bueno B
AD  - Department of Nephrology, Costa del Sol Hospital, Marbella, Spain.
FAU - Jimenez-Millan, Anabel
AU  - Jimenez-Millan A
AD  - Department of Endocrinology, University Hospital of Puerto Real, Puerto Real, 
      Spain.
FAU - Rivas Ruiz, Francisco
AU  - Rivas Ruiz F
AD  - Research Unit, Costa del Sol Hospital, Marbella, Spain.
FAU - Miramontes-Gonzalez, Jose P
AU  - Miramontes-Gonzalez JP
AD  - Department of Internal Medicine, Rio Hortega University Hospital, Valladolid 
      University, Valladolid, Spain - jpmiramontes@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20230620
PL  - Italy
TA  - Minerva Endocrinol (Torino)
JT  - Minerva endocrinology
JID - 101777342
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 53AXN4NNHX (semaglutide)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Glycated Hemoglobin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Glucagon-Like Peptides/therapeutic use/adverse effects/administration & dosage
MH  - Female
MH  - *Diabetes Mellitus, Type 2/drug therapy/blood
MH  - Male
MH  - Retrospective Studies
MH  - *Hypoglycemic Agents/therapeutic use/adverse effects/administration & dosage
MH  - Aged, 80 and over
MH  - Treatment Outcome
MH  - Weight Loss/drug effects
MH  - Spain
MH  - Glycated Hemoglobin/analysis
MH  - Follow-Up Studies
MH  - Body Weight/drug effects
MH  - Glucagon-Like Peptide 1
EDAT- 2023/06/20 06:42
MHDA- 2025/10/06 12:31
CRDT- 2023/06/20 03:37
PHST- 2025/10/06 12:31 [medline]
PHST- 2023/06/20 06:42 [pubmed]
PHST- 2023/06/20 03:37 [entrez]
AID - S2724-6507.23.03985-4 [pii]
AID - 10.23736/S2724-6507.23.03985-4 [doi]
PST - ppublish
SO  - Minerva Endocrinol (Torino). 2025 Sep;50(3):296-301. doi: 
      10.23736/S2724-6507.23.03985-4. Epub 2023 Jun 20.